TITLE

A Banker Turned CFO Believes in Service

AUTHOR(S)
Santini, Laura
PUB. DATE
March 2004
SOURCE
Investment Dealers' Digest;3/29/2004, Vol. 70 Issue 13, p28
SOURCE TYPE
Trade Publication
DOC. TYPE
Interview
ABSTRACT
This article interviews Robert Hugin, chief financial officer of biotechnology company Celegene Corp. Regarding interests in financing for the company, Hugin informs that the company has a very high cash position, and turned profitable for the first time last year. But overall, biotechnology industry is much less volatile in terms of the opening and closing of markets. The company did a large equity offering in February of 2000. It raised almost $350 million. The company's R&D spending has increased by almost 40 percent a year over the last five years.
ACCESSION #
12660559

 

Related Articles

  • Stock to watch: Celgene. Garver, Rob // Business News New Jersey;12/07/98, Vol. 11 Issue 44, p14 

    Monitors the market performance of the stock of Warren, New Jersey-based biotechnology firm, Celgene. Earnings per share for the third quarter of fiscal year 1998; Potential uses of the drug Thalomid.

  • WALL STREET CHOICE.  // Medical Marketing & Media;Mar2004, Vol. 39 Issue 3, p32 

    Analyzes the stock investment potential of biotechnology company, Celgene Corp. Drugs manufactured by the company that will earn benefits for the firm; Factors affecting the company's stock performance; Target stock price.

  • Biotech Blow Out. Fretz, Deirdre // njbiz;8/4/2003, Vol. 16 Issue 31, p30 

    Reports on an increase in the value of the stocks of Celgene, a biotechnology company based in Warren, New Jersey, as of August 2003. Impact of the drug Thalomid on the revenue of the company; Earnings posted by the company for the last two quarters; Expectations on the launch of Revimid by...

  • OncoMed, Celgene strike deal. Investor's Business Daily // Investors Business Daily;12/ 4/2013, pA02 

    Shares of biotech startup

  • Celgene still a Buy.  // Dow Theory Forecasts;10/14/2013, Vol. 69 Issue 41, p6 

    The article focuses on the stocks of biopharmaceutical company Celgene Corp.

  • EX-BANKERS FIND JOY IN CORPORATE AMERICA. Santini, Laura // Investment Dealers' Digest;10/21/2002, Vol. 68 Issue 40, p52 

    Focuses on the career of chief financial officer (CFO) in the financing sector. Impact of CFO's responsibilities on bankers; Shift of career type; Effect of accounting scandals on employees' records.

  • Stocks to Watch: Booming Biotechs. Sundaramorthy, Geeta // Business News New Jersey;02/22/2000, Vol. 13 Issue 8, p16 

    Provides information on New Jersey biotechnology firms whose stock prices increased during the week of February 22, 2000. Cytogen; Celgene; Integra LifeSciences Holdings; Immunomedics.

  • FINANCINGS ROUNDUP.  // BioWorld Today;4/28/2009, Vol. 20 Issue 80, p3 

    This section offers news briefs on the financial performance of biotechnology companies. The board of directors of Celgene Corp. have authorized the repurchase of up to $500 million of the company's common stock through April 2011. ProtAffin AG has completed a $18.4 million Series B equity...

  • How Celgene Became One Of The Big Winning Stocks Of 2013. KEN SHREVE // Investors Business Daily;12/27/2013, pB01 

    A strong year for the market in 2013 resulted in plenty of big moves by high-quality growth stocks. It's no surprise that their moves started the way they often do — by breaking out of bases in heavy soon after a market follow-through.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics